Stock Scorecard



Stock Summary for Resmed Inc (RMD) - $255.80 as of 11/26/2025 3:34:22 PM EST

Total Score

20 out of 30

Safety Score

65 out of 100

Currently on the following lists
Dividend Stock List
Tim's Recommendation
Buy

Growth List Algorithm Criteria for RMD

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RMD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RMD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for RMD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for RMD (65 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 7
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 1
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 6
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for RMD

Peter C Farrell Exercises Options, Realizes $1.65M - ResMed ( NYSE:RMD ) 11/19/2025 3:01:00 PM
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio 11/14/2025 12:30:00 AM
Nyxoah ( NYXH ) Q3 2025 Earnings Call Transcript 11/13/2025 10:33:00 PM
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio 11/13/2025 9:36:00 PM
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio - Nyxoah ( NASDAQ:NYXH ) 11/13/2025 9:35:00 PM
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete? 11/12/2025 7:00:00 PM
3 Rule Breaker Investing Hacks From David Gardner's Latest Book 11/9/2025 10:50:00 AM
Nvidia To Rally Around 73%? Here Are 10 Top Analyst Forecasts For Monday - Core Scientific ( NASDAQ:CORZ ) , Boeing ( NYSE:BA ) 11/3/2025 2:23:00 PM
These Analysts Revise Their Forecasts On ResMed Following Q1 Results - ResMed ( NYSE:RMD ) 10/31/2025 1:24:00 PM
Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand 10/31/2025 12:22:00 PM

Financial Details for RMD

Company Overview

Ticker RMD
Company Name Resmed Inc
Country USA
Description ResMed Inc. (RMD) is a leading healthcare technology company based in San Diego that specializes in cloud-connected devices and software for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. The company is dedicated to elevating patient outcomes through cutting-edge digital health innovations while streamlining clinical effectiveness and operational efficiencies for healthcare providers. As a pioneer in the respiratory care sector, ResMed is well-positioned for significant growth, underpinned by its strategic global market expansion and the rising demand for integrated respiratory solutions among patients worldwide.
Sector Name HEALTHCARE
Industry Name MEDICAL INSTRUMENTS & SUPPLIES
Most Recent Quarter 9/30/2025
Next Earnings Date 1/22/2026

Stock Price History

Last Day Price 255.80
Price 4 Years Ago 251.31
Last Day Price Updated 11/26/2025 3:34:22 PM EST
Last Day Volume 812,363
Average Daily Volume 1,252,326
52-Week High 293.11
52-Week Low 198.60
Last Price to 52 Week Low 28.80%

Valuation Measures

Trailing PE 25.64
Industry PE 408.09
Sector PE 88.38
5-Year Average PE 45.31
Free Cash Flow Ratio 26.98
Industry Free Cash Flow Ratio 40.57
Sector Free Cash Flow Ratio 28.18
Current Ratio Most Recent Quarter 2.89
Total Cash Per Share 9.48
Book Value Per Share Most Recent Quarter 41.94
Price to Book Ratio 5.98
Industry Price to Book Ratio 3.45
Sector Price to Book Ratio 32.98
Price to Sales Ratio Twelve Trailing Months 6.96
Industry Price to Sales Ratio Twelve Trailing Months 47.67
Sector Price to Sales Ratio Twelve Trailing Months 15.65
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 145,966,000
Market Capitalization 37,338,102,800
Institutional Ownership 65.62%

Dividends

Ex-Dividend Date 11/13/2025
Previous Dividend Amount 0.6000
Current Dividend Amount 0.6000
Total Years Dividend Increasing Dividend Contender - Increasing for 13 Years
Trailing Annual Dividend Rate 2.26
Trailing Annual Dividend Yield 0.88%
Forward Annual Dividend Rate 2.40
Forward Annual Dividend Yield 0.94%
5-Year Dividend Payments Count 20
3-Year Average Dividend Yield 0.99%
5-Year Average Dividend Yield 0.87%
1-Year Dividend Growth Rate Percentage 11.88%
3-Year Dividend Growth Rate Percentage 10.83%
5-Year Dividend Growth Rate Percentage 8.68%
All-Time Dividend Growth Rate Percentage 8.60%
Dividend Payout Ratio 23.13%

Income Statement

Quarterly Earnings Growth YOY 12.30%
Annual Earnings Growth 37.20%
Reported EPS 12 Trailing Months 9.77
Reported EPS Past Year 2.55
Reported EPS Prior Year 9.55
Net Income Twelve Trailing Months 1,437,904,000
Net Income Past Year 1,400,723,000
Net Income Prior Year 1,020,951,000
Quarterly Revenue Growth YOY 9.10%
5-Year Revenue Growth 11.72%
Operating Margin Twelve Trailing Months 34.60%

Balance Sheet

Total Cash Most Recent Quarter 1,383,848,000
Total Cash Past Year 1,209,450,000
Total Cash Prior Year 238,361,000
Net Cash Position Most Recent Quarter 975,187,000
Net Cash Position Past Year 551,058,000
Long Term Debt Past Year 658,392,000
Long Term Debt Prior Year 697,313,000
Total Debt Most Recent Quarter 408,661,000
Equity to Debt Ratio Past Year 0.90
Equity to Debt Ratio Most Recent Quarter 0.94
Total Stockholder Equity Past Year 5,967,859,000
Total Stockholder Equity Prior Year 4,864,043,000
Total Stockholder Equity Most Recent Quarter 6,121,264,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 1,767,156,000
Free Cash Flow Per Share Twelve Trailing Months 12.11
Free Cash Flow Past Year 1,661,723,000
Free Cash Flow Prior Year 1,286,404,000

Options

Put/Call Ratio 0.86
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -5.70
MACD Signal -5.87
20-Day Bollinger Lower Band 240.20
20-Day Bollinger Middle Band 267.36
20-Day Bollinger Upper Band 294.52
Beta 0.87
RSI 32.73
50-Day SMA 247.65
150-Day SMA 214.58
200-Day SMA 215.15

System

Modified 11/25/2025 7:55:55 AM EST